Hexagon Capital Partners LLC Increases Stake in Moderna,
December 29, 2022
Trending News 🌥️
Moderna ($NASDAQ:MRNA), Inc. is a biotechnology company that specializes in the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines. The company is based in Cambridge, Massachusetts and is publicly traded on the Nasdaq stock exchange. Moderna focuses on using mRNA to drive the development of treatments for cancer, infectious diseases, rare genetic diseases and cardiovascular diseases. Hexagon Capital Partners’ decision to increase its stake in Moderna is a strong vote of confidence in the company’s potential. In addition to increasing its stake in Moderna, Hexagon Capital Partners has also bought additional shares of other companies in the biotech sector. The firm recently purchased additional shares of Regeneron Pharmaceuticals, Inc., which focuses on developing treatments for autoimmune and inflammatory diseases.
Hexagon’s increased investments in these companies show that it is confident about the future of the biotech sector. The increased stake by Hexagon Capital Partners in Moderna is a strong sign of confidence in the company’s long-term outlook and potential. With its mRNA-based treatments and vaccines, Moderna is well-positioned to benefit from the growing demand for biotech products. With Hexagon’s increased stake, investors can expect to see even more bullish sentiment surrounding Moderna stock in the near future.
Market Price
On Tuesday, Moderna, Inc. experienced a 9.5% drop in their stock price as it opened at $199.9 and closed at $180.2, lower than the previous closing price of $199.1. Hexagon’s decision to increase their stake in Moderna could be seen as a vote of confidence in the company’s financial health, as well as its potential for future growth. This could be seen as a positive for the company, as it signals that Hexagon believes in Moderna’s ability to continue growing and delivering strong results. It is also worth noting that this increase in Hexagon’s stake in Moderna comes at a time when the company is continuing to expand its reach, both domestically and internationally.
With the launch of its new mRNA vaccine, Moderna has been able to rapidly expand its presence in countries around the world, and this move by Hexagon could be seen as further confirmation of the company’s potential for long-term success. Overall, Hexagon’s decision to increase its stake in Moderna could be seen as a positive sign for the company’s future prospects. Although the stock has recently dropped 9.5%, Hexagon’s move could be a sign that it believes in the future of the company and is willing to back it with further investments. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Moderna. More…
| Total Revenues | Net Income | Net Margin |
| 20.68k | 11.77k | 57.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Moderna. More…
| Operations | Investing | Financing |
| 6.63k | -5.27k | -3.88k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Moderna. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 26.06k | 8.06k | 46.49 |
Key Ratios Snapshot
Some of the financial key ratios for Moderna are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 565.0% | – | 64.6% |
| FCF Margin | ROE | ROA |
| 30.0% | 46.4% | 32.0% |
VI Analysis
Investors often look for companies with strong fundamentals that reflect their long-term potential. VI app simplifies this process by providing a visual representation of a company’s fundamentals. For example, the VI Star Chart classifies MODERNA as a ‘gorilla’, which is a type of company that has achieved strong and sustained revenue or earning growth due to its strong competitive advantage. This can make MODERNA an attractive option for investors who are seeking long-term growth potential. In addition, MODERNA has a high health score of 7/10 with regard to its cashflows and debt. This indicates that the company is capable of paying off debt and funding future operations. Furthermore, MODERNA is strong in asset, growth, and profitability, and weak in dividend. This makes it an ideal option for investors who are looking for capital gains rather than regular dividend income. Its high health score and strong performance in asset, growth, and profitability make it an attractive option for investors seeking out capital gains and long-term growth. More…
VI Peers
Moderna Inc is a biotechnology company that develops and manufactures drugs, vaccines, and diagnostics. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. Moderna Inc’s main competitors are BioNTech SE, Pfizer Inc, and Novavax Inc.
– BioNTech SE ($NASDAQ:BNTX)
BioNTech SE is a German biotechnology company founded in 2008. The company has a market cap of 33.72B as of 2022 and a Return on Equity of 71.82%. BioNTech focuses on the development of innovative therapies for the treatment of cancer and other diseases. The company’s most advanced product is a vaccine for the treatment of human papillomavirus (HPV). BioNTech is also developing a number of other vaccines and therapies for the treatment of cancer, infectious diseases, and autoimmune disorders.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a global pharmaceutical company with a market cap of 247.45B as of 2022. The company’s return on equity is 24.63%. Pfizer’s products include prescription and over-the-counter medicines, vaccines, and animal health products. The company operates in over 150 countries and serves patients and customers across the globe.
– Novavax Inc ($NASDAQ:NVAX)
Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Novavax’s market cap as of 2022 is 1.46B and its ROE is 487.21%. The company’s lead product candidates are NVX-CoV2373, which is in Phase III clinical trials for the prevention of COVID-19, and ResVax, which is in Phase III clinical trials for the prevention of respiratory syncytial virus (RSV) disease.
Summary
Moderna (MRNA) is a biotechnology company focused on the development and manufacturing of mRNA-based therapeutics and vaccines. Its stock has seen significant volatility in recent months, with Hexagon Capital Partners LLC recently increasing its stake in the company. Despite this, the stock price has moved down on the same day. For investors considering investing in Moderna, it is important to consider the potential risks and rewards associated with investing in a biotechnology company.
These include the potential for significant upside if the company’s products prove successful but also the potential for significant losses if its products fail to meet expectations. It is also important to do thorough research into the company’s finances and competitive landscape to ensure that an investment in Moderna is well-informed.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
